30th April 2022 | Pharma Updates

Cipla seeking for a new identity, from pills to wellness

Cipla Pharmaceuticals wants to be more than just a pharmaceutical company that sells pills; it wants to play a deeper part in a patient’s journey from illness to wellness.

Pfizer's Covid drug fails an infection prevention test

Pfizer said in a statement that the medicine, Paxlovid, failed to reach its primary target of significantly lowering the risk of Covid-19 infection in people exposed to the virus through household contact.

NTAGI panel advises including Covovax in the vaccination drive for children aged 12 to 17

NTAGI’s Standing Technical Sub Committee has recommended that the Serum Institute’s Covovax be included in the national COVID-19 vaccination programme for children aged 12 to 17 years.

COVID vaccine developed by GSK and SK Bioscience submitted for approval in South Korea

GlaxoSmithKline’s COVID-19 vaccine candidate, developed in collaboration with SK bioscience has been submitted for regulatory approval in South Korea following positive Phase III clinical data.

Pfizer initiates gene therapy trial in the United States

After the Food and Drug Administration lifted its hold on a late-stage research, Pfizer announced it would start the first U.S. trial sites for its experimental gene treatment for a muscle-wasting disorder.

Ayu Health raises $27 million from the Nilekani Fund and others

Ayu Health, a healthcare startup, has raised USD 27 million (about Rs 205 crore) in a series-B investment led by Fundamentum Partnership, an early growth-stage firm created by Nandan Nilekani and Sanjeev Aggarwal.

Bristol Myers Squibb's oral heart disease medication approved by the FDA

Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) has been approved by the USFDA for the treatment of people with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy.